{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:51:21Z","timestamp":1760575881793,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T00:00:00Z","timestamp":1676160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jfma.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T16:02:51Z","timestamp":1677859371000},"page":"564-573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy"],"prefix":"10.1016","volume":"122","author":[{"given":"Meng-Ju","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-7941","authenticated-orcid":false,"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyh-Ming","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jfma.2023.02.002_bib1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jfma.2023.02.002_bib2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jfma.2023.02.002_bib3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"issue":"8","key":"10.1016\/j.jfma.2023.02.002_bib4","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.jfma.2023.02.002_bib5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","article-title":"Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients","volume":"14","author":"Jeng","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2023.02.002_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/apt.15053","article-title":"Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir","volume":"49","author":"Kuo","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.jfma.2023.02.002_bib7","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jfma.2023.02.002_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2023.02.002_bib9","first-page":"1","article-title":"Evaluation of cytokine profile in cervicovaginal lavage specimens of women having asymptomatic reproductive tract infections","author":"Aranha","year":"2022","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.jfma.2023.02.002_bib10","article-title":"Cytokine release by human bone marrow stromal cells isolated from osteoarthritic and diabetic osteoarthritic patients in vitro","author":"Loh","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"6","key":"10.1016\/j.jfma.2023.02.002_bib11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.transproceed.2019.04.046","article-title":"Assessment of cytokines, biochemical markers of malnutrition and frailty syndrome patients considered for lung transplantation","volume":"51","author":"Stanjek-Cichoracka","year":"2019","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.jfma.2023.02.002_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jac\/dkab444","article-title":"Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis","volume":"77","author":"Virseda-Berdices","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jfma.2023.02.002_bib13","first-page":"93","article-title":"Evaluation of serum IFN- and IL-5 levels in response to entecavir therapy in patients with chronic hepatitis B virus infection","volume":"25","author":"Badary","year":"2018","journal-title":"Egypt J Immunol"},{"issue":"4","key":"10.1016\/j.jfma.2023.02.002_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/QAI.0b013e3182185276","article-title":"Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12\/IL-10 balance in human primary cells","volume":"57","author":"Melchjorsen","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.jfma.2023.02.002_bib15","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.4238\/2015.April.13.16","article-title":"Changes to the migratory inhibitory factor, IL-17, and IL-10 levels in serum from chronic hepatitis B patients and clinical significance following Baraclude(\u00ae) treatment","volume":"14","author":"Yu","year":"2015","journal-title":"Genet Mol Res"},{"issue":"1","key":"10.1016\/j.jfma.2023.02.002_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/cmi.2010.37","article-title":"Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies","volume":"8","author":"Jiang","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jfma.2023.02.002_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ebiom.2016.10.009","article-title":"Equivalent decline in inflammation markers with tenofovir disoproxil fumarate vs. Tenofovir alafenamide","volume":"13","author":"Funderburg","year":"2016","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.jfma.2023.02.002_bib18","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep.30956","article-title":"Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection","volume":"71","author":"Murata","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2023.02.002_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hep.23273","article-title":"Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B","volume":"51","author":"Zhang","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jfma.2023.02.002_bib20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1440-1746.2009.06154.x","article-title":"Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients","volume":"25","author":"Wu","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jfma.2023.02.002_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri2735","article-title":"How are TH2-type immune responses initiated and amplified?","volume":"10","author":"Paul","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jfma.2023.02.002_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12016-014-8465-4","article-title":"Cytokine-mediated immunopathogenesis of hepatitis B virus infections","volume":"50","author":"Li","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"10.1016\/j.jfma.2023.02.002_bib23","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/eji.1830271015","article-title":"Induction of T cell adhesion to extracellular\u00a0matrix or endothelial cell ligands by soluble or matrix-bound interleukin-7","volume":"27","author":"Ariel","year":"1997","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.jfma.2023.02.002_bib24","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1182\/blood.V90.7.2690","article-title":"Interleukin-7 upregulates the interleukin-2-gene expression in activated human T lymphocytes at the transcriptional level by enhancing the DNA binding activities of both nuclear factor of activated T cells and activator protein-1","volume":"90","author":"Gringhuis","year":"1997","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jfma.2023.02.002_bib25","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.36068","article-title":"Interleukin-7 in patients with chronic hepatitis B may have effect on T follicular helper cells and specific cellular immunity","volume":"16","author":"Zhong","year":"2016","journal-title":"Hepat Mon"},{"issue":"10","key":"10.1016\/j.jfma.2023.02.002_bib26","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V97.10.2983","article-title":"A potential role for interleukin-7 in T-cell homeostasis","volume":"97","author":"Fry","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jfma.2023.02.002_bib27","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1073\/pnas.91.9.3764","article-title":"Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice","volume":"91","author":"Guidotti","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6552","key":"10.1016\/j.jfma.2023.02.002_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-gamma production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jfma.2023.02.002_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.19.1.423","article-title":"Interleukin-18 regulates both Th1 and Th2 responses","volume":"19","author":"Nakanishi","year":"2001","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.jfma.2023.02.002_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jfma.2023.02.002_bib31","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1128\/JVI.76.7.3570-3574.2002","article-title":"Inhibition of hepatitis B virus replication by interferon requires proteasome activity","volume":"76","author":"Robek","year":"2002","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.jfma.2023.02.002_bib32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jfma.2021.09.002","article-title":"Serum cytokine\/chemokine profiles predict hepatitis B reactivation in HBV\/HCV co-infected subjects receiving direct-acting antiviral agents","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"10.1016\/j.jfma.2023.02.002_bib33","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1172\/JCI135616","article-title":"Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection","volume":"130","author":"Cheng","year":"2020","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jfma.2023.02.002_bib34","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.60377","article-title":"Serum levels of interleukin-4, interleukin-10 and interferon-\u03b3 in patients with chronic hepatitis B infection","volume":"18","author":"Hosseini Khorami","year":"2018","journal-title":"Hepat Mon"},{"issue":"10","key":"10.1016\/j.jfma.2023.02.002_bib35","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jfma.2023.02.002_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14218\/JCTH.2021.00160","article-title":"Change of cytokines in chronic hepatitis B patients and HBeAg are positively correlated with HBV RNA, based on real-world study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Clin Transl Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:49:35Z","timestamp":1760539775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664623000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0929664623000384"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2023.02.002","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}